openPR Logo
Press release

IgA Nephropathy (IgAN) Pipeline Assessment - FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies

08-30-2022 09:20 AM CET | Health & Medicine

Press release from: DelveInsight Business Research

IgA Nephropathy (IgAN) Pipeline

IgA Nephropathy (IgAN) Pipeline

IgA Nephropathy pipeline constitutes 30+ key companies continuously working towards developing 30+ IgA Nephropathy treatment therapies, analyzes DelveInsight

IgA nephropathy is one of the common forms of glomerulonephritis caused by the deposition of IgA immunoglobulin in the glomerular basement membrane. Immune-mediated damage to the basement membrane results in hematuria and renal insufficiency. Berger was the first to describe the disease, so it also carries the name Berger disease.

"IgA Nephropathy (IgAN) Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the IgA Nephropathy Market.

The IgA Nephropathy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

To know more about the IgA Nephropathy Market, Have a look: https://www.delveinsight.com/report-store/iga-nephropathy-igan-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

DelveInsight's IgA Nephropathy Pipeline Report covers around 30+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Emerging IgA Nephropathy Drugs Under Different Phases of Clinical Development Include:
• Atrasentan: Chinook Therapeutics
• Sparsentan: Travere Therapeutics
And Many Others

Further IgA Nephropathy product details are provided in the report. Download the IgA Nephropathy Pipeline report to learn more about the emerging IgA Nephropathy therapies at: https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

IgA Nephropathy (IgAN) Pipeline Analysis

The report provides insights into:

The report provides detailed insights about companies that are developing therapies for the treatment of IgA Nephropathy with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the IgA Nephropathy Treatment.
IgA Nephropathy key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
IgA Nephropathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the IgA Nephropathy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Request for Sample PDF for IgA Nephropathy Pipeline Report - https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key companies in the IgA Nephropathy (IgAN) Therapeutics Market include:
Chinook Therapeutics, Travere Therapeutics, Aravive, Aduro Biotech, Chinook Therapeutics, Transcenta Holding, Novartis Pharmaceuticals, Ionis Pharmaceuticals, Merck Serono, ZymoGenetics and Others.

Request for Sample PDF Report for IgA Nephropathy Pipeline Assessment - https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. IgA Nephropathy Current Treatment Patterns
4. IgA Nephropathy - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. IgA Nephropathy Late Stage Products (Phase-III)
7. IgA Nephropathy Mid-Stage Products (Phase-II)
8. IgA Nephropathy Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. IgA Nephropathy Discontinued Products
13. IgA Nephropathy Product Profiles
14. Key Companies in the IgA Nephropathy Market
15. Key Products in the IgA Nephropathy Therapeutics Segment
16. Dormant and Discontinued Products
17. IgA Nephropathy Unmet Needs
18. IgA Nephropathy Future Perspectives
19. IgA Nephropathy Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report for IgA Nephropathy Drugs and Therapies - https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Trending Reports:
• T-Cell-Prolymphocytic Leukemia Market: https://www.delveinsight.com/report-store/t-cell-prolymphocytic-leukemia-market
• Bone Grafts And Substitutes Market: https://www.delveinsight.com/report-store/bone-grafts-and-substitutes-market
• Hip Replacement Devices Market: https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
• Hepatic Encephalopathy Epidemiology Forecast: https://www.delveinsight.com/report-store/hepatic-encephalopathy-epidemiology-forecast
• Familial Primary Pulmonary Hypertension Market: https://www.delveinsight.com/report-store/familial-primary-pulmonary-hypertension-market
• Global Electrophysiology Devices Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Age Related Vision Dysfunction Market: https://www.delveinsight.com/report-store/age-related-vision-dysfunction-market
• Emesis Market: https://www.delveinsight.com/report-store/emesis-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release IgA Nephropathy (IgAN) Pipeline Assessment - FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies here

News-ID: 2719914 • Views:

More Releases from DelveInsight Business Research

Myelofibrosis Market to Double by 2034, Surpassing USD 5.6 Billion Across 7MM with 9% CAGR Growth, states DelveInsight
Myelofibrosis Market to Double by 2034, Surpassing USD 5.6 Billion Across 7MM wi …
The Myelofibrosis market across the seven major markets (7MM) is anticipated to experience significant growth, rising from approximately USD 2,602 million in 2025 to nearly USD 5,638 million by 2034, reflecting a compound annual growth rate (CAGR) of about 9% during the forecast period. In 2024, the market was valued at around USD 2.2 billion, with the United States leading at nearly USD 1.7 billion, far surpassing the EU4, the United
Triple-Negative Breast Cancer Clinical Trial Landscape Expands With 170+ Pipeline Assets, According to DelveInsight
Triple-Negative Breast Cancer Clinical Trial Landscape Expands With 170+ Pipelin …
An expanding portfolio of novel therapies for triple-negative breast cancer (TNBC) including TECENTRIQ (Hoffmann-La Roche), IPI-549 (Infinity Pharmaceuticals), Leronlimab (CytoDyn), MDNA11 (Medicenna Therapeutics), VIP236 (Vincerx Pharma), and CFI-400945 (Treadwell Therapeutics) is anticipated to significantly influence market expansion and transform the TNBC treatment landscape. DelveInsight's Triple Negative Breast Cancer Pipeline Insight report offers an extensive evaluation of more than 165 companies and over 170 therapeutic candidates advancing through the TNBC pipeline. The
Asthma Market to Witness Steady Growth Through 2034 Driven by Novel Biologics and Triple-Combination Therapies | DelveInsight
Asthma Market to Witness Steady Growth Through 2034 Driven by Novel Biologics an …
DelveInsight's latest Asthma Market Insights, Epidemiology, and Market Forecast - 2034 report provides an in-depth evaluation of current treatment practices, emerging asthma drugs, market share of individual therapies, and forecasted market trends across the seven major markets (7MM) - the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The asthma market is expected to experience sustained growth over the next decade, supported by the launch of
Restrictive Cardiomyopathy Market: Pharma Pipeline Fuels Rapid Expansion by 2024 - DelveInsight
Restrictive Cardiomyopathy Market: Pharma Pipeline Fuels Rapid Expansion by 2024 …
DelveInsight's "Restrictive Cardiomyopathy Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Restrictive Cardiomyopathy, historical and forecasted epidemiology as well as the Restrictive Cardiomyopathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. The latest healthcare forecast report provides an in-depth analysis of Restrictive Cardiomyopathy, offering comprehensive insights into the Restrictive Cardiomyopathy revenue trends, prevalence, and treatment landscape. The

All 5 Releases


More Releases for IgA

IgA Nephropathy Market Dynamics Indicate Upward Trajectory Through 2034, Reports …
The Key IgA Nephropathy Companies in the market include - Travere Therapeutics, Asahi Kasei (Calliditas Therapeutics), Vertex Pharmaceuticals, Vera Therapeutics, Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences, Shanghai Alebund Pharmaceuticals, Rohto Pharmaceutical, Wuhan Createrna Science and Technology, Guangdong Hengrui Pharmaceutical, LRx Ionis Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Travere Therapeutics, and others. DelveInsight's "IgA Nephropathy Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the IgA Nephropathy,
IgA Nephropathy Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, IgA Nephropathy pipeline constitutes 25+ key companies continuously working towards developing 30+ IgA Nephropathy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "IgA Nephropathy Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the IgA Nephropathy Market. The IgA Nephropathy Pipeline report
Multiplier Strengthens Identity Governance with Advanced IGA Solutions
Image: https://www.abnewswire.com/upload/2025/08/8c79c8224ecce453d70ad648fa16d5e9.jpg Introduction In today's rapidly evolving digital landscape, managing user identities and access rights has become a critical concern for businesses of all sizes. As organizations expand, ensuring the right individuals have the correct access to systems and data is essential for operational efficiency and security. Multiplier, a leader in innovative enterprise solutions, is empowering companies with comprehensive Identity Governance and Administration (IGA) solutions to address these challenges. IGA Solutions: The Heart
IgA Nephropathy Market Positioned for Accelerated Development Through 2032, Delv …
The Key IgA Nephropathy Companies in the market include - Travere Therapeutics, Asahi Kasei (Calliditas Therapeutics), Vertex Pharmaceuticals, Vera Therapeutics, Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences, Shanghai Alebund Pharmaceuticals, Rohto Pharmaceutical, Wuhan Createrna Science and Technology, Guangdong Hengrui Pharmaceutical, LRx Ionis Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Travere Therapeutics, and others. DelveInsight's "IgA Nephropathy Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the IgA Nephropathy,
IgA Nephropathy Drugs Market Trends And Forecast 2023-2030
Innovations and Growth Propel IgA Nephropathy Drugs Market: Global IgA Nephropathy Drugs Market Expands with Technological Advancements and Research Initiatives The IgA nephropathy drugs market is witnessing a surge in product launches driven by advancements in technology and an upswing in research and development activities. IgA nephropathy, an autoimmune disease affecting the kidneys, results in inflammation and kidney damage due to the accumulation of antibody clumps. The market is experiencing notable growth,
IgA Nephropathy Drugs Market Sales, Demands and Forecasts
The IgA Nephropathy Drugs market research report is proficient and top to bottom research by specialists on the current state of the industry. This statistical surveying report gives the most up to date industry information and industry future patterns, enabling you to distinguish the items and end clients driving income development and benefit. It centres around the real drivers and restrictions for the key players and present challenge status with